UNDERSTANDING

Genomic and Hereditary Cancer Risk

A HANDBOOK FOR ONCOLOGY NURSES

By
Suzanne M. Mahon, DNS, RN, AOCN®, AGN-BC, FAAN
Editors and authors of books and guidelines provided by the Oncology Nursing Society are expected to disclose to the readers any significant financial interest or other relationships with the manufacturer(s) of any commercial products. A vested interest may be considered to exist if a contributor is affiliated with or has a financial interest in commercial organizations that may have a direct or indirect interest in the subject matter. A “financial interest” may include, but is not limited to, being a shareholder in the organization; being an employee of the commercial organization; serving on an organization’s speakers bureau; or receiving research funding from the organization. An “affiliation” may be holding a position on an advisory board or some other role of benefit to the commercial organization. Vested interest statements appear in the front matter for each publication.

Contributors are expected to disclose any unlabeled or investigational use of products discussed in their content. This information is acknowledged solely for the information of the readers.

The author provided the following disclosure and vested interest information:
The author had no relevant information to disclose.
The Oncology Nursing Society (ONS) produces some of the most highly respected educational resources in the field of oncology nursing, including ONS’s award-winning journals, books, online courses, evidence-based resources, core competencies, videos, and information available on the ONS website at www.ons.org. ONS welcomes opportunities to license reuse of these intellectual properties to other organizations.

Licensing opportunities include the following:

- **Reprints**—Purchase high-quality reprints of ONS journal articles, book chapters, and other content directly from ONS, or obtain permission to produce your own reprints.
- **Translations**—Translate and then resell or share ONS resources internationally.
- **Integration**—Purchase a license to incorporate ONS’s oncology-specific telephone triage protocols or other resources into your institution’s EMR or EHR system.
- **Cobranding**—Display your company’s logo on ONS resources for distribution to your organization’s employees or customers.
- **Educational reuse**—Supplement your staff or student educational programs using ONS resources.
- **Customization**—Customize ONS intellectual property for inclusion in your own products or services.
- **Bulk purchases**—Buy ONS books and online courses in high quantities to receive great savings compared to regular pricing.

As you read through the pages of this book, think about whether any of these opportunities are the right fit for you as you consider reusing ONS content—and the contents of this book—for your organization.

Contact licensing@ons.org with your licensing questions or requests.
# Table of Contents

**Preface** vii

**Chapter 1. Why Nurses Need to Integrate Genomics Into Oncology Care** 1
- Introduction 1
- Precision Medicine 1
- Hereditary Risk of Developing Cancer 2
- Implications for Nurses 3
- Summary 3
- References 4

**Chapter 2. Genomic Basis of Cancer** 5
- Introduction 5
- DNA and Genomics 5
- Nomenclature 8
- Terms Encountered in Genomic Care 9
- Indicators of Hereditary Risk for Developing Cancer 11
- Laboratory Considerations 14
- Summary 17
- References 18

**Chapter 3. Genomic Risk Assessment and Testing** 21
- Introduction 21
- Risk Assessment 21
- The Importance of Family Medical History 23
- Developing a Pedigree 24
- Risk Calculations 25
- Pretest Counseling 28
- Selection of How and Who to Test 32
- Possible Genomic Testing Results 37
- After Genomic Testing 40
- Implications for Family Members 41
- Summary 42
- References 45

**Chapter 4. Direct-to-Consumer Genetic Testing** 49
- Introduction 49
- Effects of Direct-to-Consumer Genetic Testing 49
- How is Direct-to-Consumer Genetic Testing Accomplished? 52
- Benefits, Risks, and Limitations of Direct-to-Consumer Genetic Testing 53
- Raw Data 55
- Implications for Practice 56
- Summary 58
- References 59

**Chapter 5. Risks and Management Recommendations for Specific Hereditary Cancer Syndromes** 61
- Introduction 61
- AIP 62
- ALK 63
- APC (APC-Associated Polyposis Conditions: Familial Adenomatous Polyposis) 64
- ATM 66
- AXIN2 68
BAP1 69
BARD1 70
BMPR1A 71
BRCA1 and BRCA2 72
BRIP1 74
CD73 75
CDH1 76
CDK4 78
CDKN1B and CDKN2A 79
CHEK2 80
DICER1 82
EPCAM, MLH1, MSH2, MSH3, MSH6, and PMS2 (Lynch Syndrome) 83
FANCC 85
FH 86
FLCN (Birt-Hogg-Dubé Syndrome) 87
GREM1 and SCG5 (Hereditary Mixed Polyposis Syndrome) 89
HOXB13 89
MAX, SDHA, SDHAF2, SDHB, SDHC, SDHD, and TMEM127 (Hereditary Paraganglioma/Pheochromocytoma Syndrome) 90
MEN1 (Multiple Endocrine Neoplasia Type 1) 92
MEN2 (Multiple Endocrine Neoplasia Type 2) 93
MET 95
MITF 96
MUTYH 97
NBN, MRE11A, and RAD50 98
NTHL1 100
NF1 (Neurofibromatosis Type 1) 101
NF2 (Neurofibromatosis Type 2) 103
PALB2 104
POLD1 and POLE1 105
POT1 106
PTCH1 and SUFU (Neviod Basal Cell Carcinoma Syndrome) 107
PTEN (Cowden Syndrome) 108
RAD51C and RAD51D 110
RB1 111
RECQL 112
SMAD4 113
STK11 (Peutz-Jeghers Syndrome) 114
TP53 (Li-Fraumeni Syndrome) 116
VHL (Von Hippel-Lindau Syndrome) 118
XRCC2 120

Glossary of Terms 121
Bibliography 125
Index 127
Collecting a family medical history is a regular component of the nursing assessment process. Patients with cancer often report that multiple family members have been diagnosed with cancer or express concern that other family members might be at increased risk for developing cancer.

As the involvement of genetics and genomics in oncology continues to grow, so too does public awareness of hereditary risk for developing cancer. This increasing awareness directly affects oncology nursing care. Although true germline (inherited) risk for developing cancer is much less common than somatic (acquired) risk for developing cancer, approximately 10% of cancer diagnoses can be attributed to germline risk. The identification of these families enables those at increased risk to engage in increased surveillance and, in some cases, risk-reducing surgery and other preventive measures, which ultimately lead to decreasing the morbidity and mortality associated with a cancer diagnosis.

In the past two decades, genetic testing for germline risk has greatly advanced. Genetic testing in oncology practice is being utilized more frequently and is best managed by genetics professionals. Genetics professionals, however, rely on healthcare providers to identify and refer patients for evaluation. Each time nurses extract a family history, they have an opportunity to assess for possible genetic risk and, when appropriate, refer patients and families to a genetics professional for further evaluation.

This book provides background on basic genetic and genomic concepts, especially related to germline risk for developing cancer. Nurses need this information to know when and why to refer patients. Nurses also need to give patients reliable information about how and why genetic and genomic testing can not only guide treatment decisions but also guide recommendations for cancer prevention and early detection. Chapter 2 describes foundational information about genomics and germline testing. Important terms appear in bold throughout the book and are defined in the Glossary.

Nurses may face questions from patients about what occurs during a consultation with a genetics professional. Patients often want to know why the test
cannot just be ordered. Genetic counseling involves multiple steps, including construction and interpretation of family pedigrees, ordering of tests, and interpretation of test results, all of which may have specific challenges. Nurses must be informed on the process so that they can reassure their patients that these steps are necessary. Chapter 3 provides an overview of the genetic counseling and testing process.

The increased awareness and direct-to-consumer marketing messages about genetic testing have prompted patients to ask more questions about genetic testing. Nurses must be able to respond to basic questions about different types of genomic testing with accurate information. If patients are concerned that healthcare professionals are not paying attention to their family history, they may turn to direct-to-consumer genetic testing, which may or may not provide the information they are seeking. Direct-to-consumer genetic testing is discussed in Chapter 4.

Following genetic testing, most genetics professionals provide detailed information about recommendations for care, including recommendations for ongoing prevention and early detection. For patients who are found to have a harmful pathogenic variant (historically known as a mutation), these recommendations can be extensive and are based on the personal and family medical history, as well as the specific pathogenic variant. Chapter 5 provides quick overviews of many of the more common germline pathogenic variants. These overviews include information on risks associated with each variant, recommendations for cancer prevention and early detection, and when to offer genetic testing. Each overview also includes reputable resources for more information.

With public awareness of genetic testing growing, nurses need a resource that provides them with more intensive information on germline cancer risk than they would typically receive during undergraduate or graduate education. This handbook provides nurses with the essentials to understand genomic and hereditary cancer risk, to assist in facilitating interprofessional care with genetics and other oncology professionals, and to provide their patients with accurate and reassuring information.